analysts asking alot of questions about Uceris impressive growth
the strong growth of Uceris has taken a couple of analysts by surprise on the Conf Call. Lots of questions on why some models missed the strong uptake.
This, coupled with the pipeline (Pediatric Uceris, Ruconest) is starting to shine a light on SNTS. Ruconest considered 'best in class' .... I think we see the SP in the high $30's as we move thru Q3 and into Q4.
During the initial presentation on the conference call - they are increasing promotion to push Uceris with 25 additional sales force. They will also, reinforce other products while on calls to MD offices. Obviously will take some time to ramp up. This is very positive. Also new Uceris studies to expand usage.